“Failure to Launch” Syndrome: How to Stop Enabling Your Grown Child
When Zeke was in high school, he struggled with anxiety and substance use problems, and he left college after the first semester. Now 25, he is living at home, and his mom Carol is frustrated. While she’s pushed him to go back to school or work, he has only held one part-time job at a local smoothie shop and quit after a few months, embarrassed that high school classmates would see him working there. Another attempt at trade school to become an electrician also didn’t take — it didn’t feel like the right fit. Now he rarely leaves the house, stays up all night playing video games or scrolling online, and sleeps most of the day.
Failure to launch syndrome, highly dependent adult children, boomerang kids — there’s no standard term or definition, but if you’re a parent in this situation you recognize it. You are worried and frustrated about your adult child’s difficulty in leaving the nest, and you don’t know what to do because everything you’ve tried so far hasn’t worked.
“These aren’t kids who come back home because they finished school, and the first job they get doesn’t pay enough for them to afford rent on an apartment,” says Theresa Welles, the Shapiro Family Director of the Bubrick Center for Pediatric OCD at the Child Mind Institute. “We’re talking about young adults who functionally have hit a wall, so to speak. They’re caught in a loop of dependency.”
What is failure to launch syndrome?
It’s not uncommon for adult children to live with their parents: According to Pew Research Center, 18 percent of adults ages 25 to 34 lived in their parents’ home in 2023, with young men more likely than young women to do so (20 percent vs. 15 percent). Young adults might leave home for a period of time and then move back in with their parents because they can’t find a job. Or for religious or cultural reasons, some adult children expect to live in the family home until they get married. Living at home is not the main criterion for determining a “failure to launch.”
While there is no official clinical definition, researchers who study this group of young adults generally categorize someone as a highly dependent adult child if they are:
- Not in school, working, or actively looking for work (though physically capable of doing so)
- Financially dependent on their parents for housing and other necessities
- Emotionally reliant on parents (i.e., needing constant reassurance that they are okay)
They usually have very limited social interactions other than online. Often, they have mental health challenges such as anxiety, depression, or OCD, which is a contributing factor, Dr. Welles says.
“They’re at the developmental stage of early adulthood, they’re figuring out who they are,” Dr. Welles says. “The fancy term in psychology is ‘individuation,’ but it’s essentially who you are, both as part of your family and separate from your family.” Highly dependent adult children haven’t made much progress in this stage for several years. Many of them want to change their life path and become more independent, but they struggle with anxiety or fear of failure and don’t follow through on the necessary steps. “Reliance on parents reduces opportunities to build autonomy, which in turn maintains that reliance,” she says. So, they remain stuck.
Dependent behaviors and parental accommodations
Young adults who are highly dependent often fall into certain patterns of behavior. They don’t do their own laundry, cook, clean, or help out around the house. They rarely leave the home and often shut themselves in their bedroom or live in the basement, avoiding talking to others in person. As a result, they rely on their parents to act as an intermediary with the outside world, such as making doctor’s appointments. They might blame their parents for their difficulties in life.
While parents may not like the situation, they struggle to get their adult child to change. So instead, they accommodate them — especially when they are concerned about their child’s mental health challenges.
“In the world of neurodiversity, accommodations are a good thing — we want accommodations for testing and sensory environments,” says Natalia Aíza, LPC, the author of the forthcoming Anxious to Launch: Parenting Strategies to Help Your Adult Child Move On. “But in the anxious-to-launch world, accommodations are actually interfering with your child becoming independent.”
Aíza gives some examples of unhelpful family accommodations: You make sure there’s food in the fridge, don’t ask them to contribute to paying bills, and may give them spending money. When they get angry or upset, you accept the behavior and feel guilty, thinking you are to blame for the situation. If they are anxious when you aren’t nearby, you don’t travel because it causes them stress. Instead of expecting them to take steps to find a therapist, you do the legwork.
“The number one behavior of the highly dependent adult child is avoidance. I cannot emphasize this enough,” Aíza says. “If your child has a full-on virtual life, that’s their social outlet. They are avoiding real-life challenges. They are avoiding working at jobs that are unpleasant. They are probably avoiding adulting tasks that should fall on them at this point. So, we swoop in and take care of those tasks for them.”
A modern version of an old problem
While adult children have lived with their parents in past generations, researchers argue that phenomenon of highly dependent adult children is on the rise, and young people today seem particularly susceptible. Adolescence is more prolonged now in many cultures, and there’s an emphasis on finding a fulfilling career, not just a job that pays the bills.
Technology contributes to the problem. Playing video games, watching videos, scrolling through social media — “these activities don’t help matters because they can do things that feel like they’re accomplishing something,” Dr. Welles says.
How to stop enabling your grown child
In Dr. Welles’s practice, she has worked with families where she initially treated the teen for anxiety or OCD, then involved the parents more deeply when the young adult had trouble launching. In one case, the son was in the habit of playing video games late at night and would sleep through class the next day. He had anxiety and depression, and his parents didn’t want to take away video games because it was the one thing he enjoyed doing. But they started turning off the Wi-Fi in the house at a certain time at night.
“It sounds so extreme, like he’s being punished,” Dr. Welles says. “But it’s about saying to him, ‘We’re going to pull back on ways we’ve accommodated that may have unintentionally made your anxiety worse.’” It was important that the parents validated his feelings, saying things like, “You feel like you’re in danger, as if you’re standing in front of a bear, and that’s really hard. But that’s the anxiety lying to you, and it won’t go away if we keep accommodating things that allow you to avoid what you need to do in order to overcome this anxiety.”
And tactics like these made a difference over time. The son is now attending college part-time and working as a server at restaurant. He has a girlfriend and has plans to save enough to move into an apartment with a friend.
Setting boundaries with your adult child
If the adult child doesn’t seem motivated to find a job, Aíza has recommended that parents take them off the family cellphone plan, giving them warning that this will happen by the next month’s bill. “This is not necessarily the most strategic financial choice” because it’s often much cheaper per person on a family plan, she acknowledges. “But it is a perfect first accommodation to remove because it is telling your adult child, ‘This is something you can handle. You can be responsible for it financially and logistically. It is something that I control, and I want to stop controlling parts of your life.’” And it’s often the motivation they need to find a job — something that can earn them $100 for the monthly cell phone bill is small enough that it feels doable.
When families take steps like these, the adult child will likely get angry or upset. “That’s hard. But think about when your kids were toddlers, and they wanted to touch a hot stove,” Dr. Welles says. “They were mad when you said, ‘No, you can’t touch that stove,’ but that didn’t mean you let them do it.”
“The good news is, generally speaking, even if there’s unhappiness in the beginning,” she continues, “pretty quickly, once they start to feel better and are doing the things that they actually care about, it can really help.”
Supporting without enabling adult children
Highly dependent adult children might accuse parents of not being supportive when they pull back on accommodations. Dr. Welles suggests communicating that you hear them and validate their feelings: “You can say things like, ‘Hey, I know this is tough or ‘I know that this makes you really nervous.’ But you combine it with the confidence that they can do it, like ‘I also know you can do it, as hard as it is.’”
Sometimes, you might think you are being supportive when you are actually enabling — like filling out a job application on behalf of the child. “Even if it works and they get an interview, you’re accommodating their anxiety,” Dr. Welles says. “But also, there’s going to be a point when you can’t do something for the child — the interview or the job itself — so the earlier that you can pull back the better.”
If your adult child has both ADHD and anxiety, you can support their executive functioning skills without accommodating the anxiety. “Maybe you sit down with them on Mondays and look at their schedule to help them determine if there’s a way you can help them organize, as opposed to you stepping in and letting them avoid things they need to do because they’re anxious about it,” Dr. Welles says.
Aíza encourages giving the adult child the minimum amount of help needed, to avoid creating another form of dependency. “It’s about noticing, ‘Am I working harder at this than they are?’” she says. “A lot of times the answer is ‘yes,’ and that’s a signal to back off and put more expectations on the child.”
Treatment for highly dependent adult children
While there is no standard treatment for highly dependent adult children, early evidence has shown a form of therapy called SPACE-FTL (Supportive Parenting for Anxious Childhood Emotions – Failure to Launch) to be promising. A variation on an effective treatment for anxiety and OCD, SPACE-FTL involves only the parents, since the adult child is often resistant to seeking help. The program helps parents reduce accommodations step by step and engage extended family and friends to help de-escalate conflict.
One tactic is to make a plan to deliver a change in accommodation in writing — for instance, explaining that you will stop paying the cellphone bill at the end of the month and why. Doing it in writing (on paper or in a text) makes the message clear and helps you remain calm and non-reactive. If you are expecting an angry or violent response, they can ask a grandparent, uncle, or family friend be in the house when you deliver the letter, since that might make the response less extreme. The relative or friend may even spend the night if the adult child is more likely to cool off when others are present.
Asking for others’ help also helps you stop blaming yourself for the situation. “A lot of parents of highly dependent adults feel shame, but this is not something happening to only one family,” Aíza says. “We need to build on our social supports and get other people on our team so that we don’t feel so isolated in this process. Your adult child may be resisting change, but you don’t have to. It might sound cruel, but our central mandate as parents is making sure our child is okay after we’re gone. We brought them on earth to survive us — that is the design.”
Frequently Asked Questions
“Failure to launch” isn’t a formal diagnosis but describes young adults who are stuck in a pattern of dependence. They’re typically not working or in school, rely on parents financially and emotionally, and struggle to move forward with adult responsibilities.
Change often starts with parents gradually pulling back on accommodations while staying supportive and calm. Set clear expectations, validate their feelings, and shift responsibility back to them in manageable steps so they can build confidence and autonomy.
The post “Failure to Launch” Syndrome: How to Stop Enabling Your Grown Child appeared first on Child Mind Institute.
Biomarkers of ASD/ADHD and Factors Affecting Anxiety and Depression in Children and Young Adults
Sponsors: University of Exeter; University of Southampton; University of Dublin, Trinity College; Carol Davila University of Medicine and Pharmacy; Jimma University; FUNDACION PARA LA INVESTIGACION HOSPITAL CLINICO SAN CARLOS; The International Centre for Diarrhoeal Disease Research, Bangladesh; University of Bari Aldo Moro
Not yet recruiting
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
Interventions: Drug: Ketamine Hydrochloride; Drug: Midazolam Hydrochloride; Behavioral: Dialectical Behavioral Therapy (DBT)
Sponsors: Joshua Rosenblat
Not yet recruiting
Anxiety and Depression Associated With the Dependent Use of Generative AI in Medical Students: Cross-Sectional Study
Background: The growing integration of artificial intelligence (AI) in higher education has transformed learning processes but also raised concerns about potential mental health risks. Medical students represent a particularly vulnerable group due to high academic stress and increasing reliance on generative AI tools for study and decision-making tasks. Despite this, the relationship between AI dependence and psychological distress remains underexplored in Latin American contexts. Objective: This study aimed to evaluate the association between generative AI dependence and levels of stress, anxiety, and depression among medical students. Methods: A cross-sectional study was conducted with 187 human medicine students from a Peruvian university during the first academic semester of 2025. The Dependence on Artificial Intelligence Scale and the Depression, Anxiety, and Stress Scale–21 were applied. Negative binomial regression models, both crude and adjusted for sex, age, income, and year of study, were used to assess associations, reporting rate ratios (RRs) and 95% CIs. Results: Participants had a median age of 22 (IQR 19‐24) years, and 58.8% (110/187) were female. The median Dependence on Artificial Intelligence Scale score was 10 (IQR 7‐14). Generative AI dependence showed significant correlations with anxiety (ρ=0.336, 95% CI 0.22‐0.44) and depression (ρ=0.316, 95% CI 0.20‐0.43) and a smaller correlation with stress (ρ=0.277, 95% CI 0.16‐0.39). In the adjusted regression models, each 1-point increase in generative AI dependence was associated with a 5% higher expected anxiety score (RR 1.05, 95% CI 1.01‐1.09; =.01) and a 4% higher depression score (RR 1.04, 95% CI 1.01‐1.08; =.03), whereas the association with stress was positive but nonsignificant (RR 1.03, 95% CI 1.00‐1.07; =.08). Fifth-year students had significantly greater anxiety levels than their sixth-year peers (RR 1.82, 95% CI 1.09‐3.01; =.02). No significant effects were observed for sex, age, or income. Conclusions: This study empirically examined generative AI dependence as a distinct behavioral construct and its association with mental health symptoms in medical students. Unlike prior research, this study evaluated psychological dependence on generative AI and modeled its relationship with anxiety and depression using appropriate count-based regression techniques. By providing early evidence from a Latin American context, it contributes to the emerging field of digital mental health and medical education research. These findings underscore the need for universities to promote balanced and responsible AI use, integrate digital literacy with mental health support strategies, and develop preventive policies that mitigate potential maladaptive reliance on generative AI tools.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/63c5cab6261231002a3eb9a11707995f" />
Psilocybin-Induced Brain Changes May Explain Therapeutic Effects
Researchers at University of California, San Francisco and Imperial College London have shown that a single dose of psilocybin, the psychedelic compound found in magic mushrooms, causes likely anatomical brain changes that last for up to a month after the experience.
The study, involving healthy volunteers who had never taken a psychedelic, links temporary shifts in brain “entropy”—which is the diversity of neural activity occurring in the brain—to insight. This suggests the psychedelic trip itself is important to the drug’s longer term therapeutic effects.
The researchers found that a high dose of psilocybin led to increased entropy in the minutes and hours after taking the drug. The degree of entropy predicted how much insight, or emotional self-awareness, the participants felt the next day; and this, in turn, forecasted improvements in their sense of wellbeing a month later.
The findings may help to explain psilocybin’s therapeutic effects on conditions such as depression, anxiety, and addiction. “Psychedelic means ‘psyche-revealing,’ or making the psyche visible,” said senior author Robin Carhart-Harris, PhD, the Ralph Metzner distinguished professor of neurology at UCSF. “Our data shows that such experiences of psychological insight relate to an entropic quality of brain activity and how both are involved in causing subsequent improvements in mental health. It suggests that the trip—and its correlates in the brain—is a key component of how psychedelic therapy works.” Carhart-Harris is senior and corresponding author of the team’s published paper in Nature Communications, titled “Human brain changes after first psilocybin use.”
“Psychedelics have robust effects on acute brain function and long-term behavior but whether they also cause enduring functional and anatomical brain changes is largely unknown,” the authors wrote. Psilocybin is the precursor of the compound psilocin, a serotonin receptor agonist. “Converging evidence supports a role for serotonin 2A receptor (5-HT2AR) agonism in eliciting the characteristic brain and subjective effects of this and related psychedelics in humans,” the team continued.
For their newly reported study, Carhart-Harris and colleagues carried out an exploratory, placebo-controlled, within-patient study in 28 psychedelic-naïve participants who each received a single, high-dose (25 mg) of psilocybin. The researchers used an assortment of brain imaging and brain measurement techniques, some of which were carried out during the peak of the psychedelic experience, as well as before and one-month after drug administration. “This was an exploratory, hypothesis-generating mechanistic study in healthy volunteers,” the authors noted. None of the 28 people in the study had a diagnosed mental health condition, which gave the scientists greater freedom to do more testing.
In the first part of the experiment the subjects were given a 1 mg dose of psilocybin, which the researchers regarded as a placebo, and were then monitored with EEG, which records brain activity from electrodes on the scalp. Over the next few weeks, the researchers measured their subjects’ psychological insight, wellbeing, and cognitive ability. They examined brain activity with functional MRI (fMRI) and brain connectivity with diffusion tensor imaging (DTI).
One month after the placebo, the subjects were given 25 mg of psilocybin, a dose capable of eliciting a strong psychedelic trip. During the experience, researchers again measured the subjects’ brain activity with EEG, and in the following weeks they repeated the same tests they had given after the 1 mg dose.
This enabled the scientists to compare the effects of the psychedelic trip on the brain and mind to the effects of the placebo. “The multimodal neuroimaging design allowed us to observe changes in brain function and (potential) anatomy from 1-h (EEG) to 1-month (DTI) after high-dose psilocybin,” they explained.
The investigators found that within 60 minutes of taking the 25 mg dose of psilocybin, EEG revealed higher entropy, suggesting that the brain was processing a richer body of information under the psychedelic. A month later, the researchers looked at their subjects’ brains using DTI, which measures the diffusion of water along neural tracts in the brain, and found that they were denser and had more integrity. This is the opposite of what happens in aging, which makes these tracts more diffuse.
The researchers cautioned that more work needs to be done to better understand the meaning of this finding, but the result is a never-before-seen sign of how psychedelics can change the brain. ”The inclusion of DTI enabled us to test for long-term changes in the integrity of white matter tracts post psilocybin,” the authors stated. “Results revealed decreased axial diffusivity in prefrontal-subcortical tracts 1-month post 25mg psilocybin.”
The day after the 25 mg dose, all but one of the 28 subjects rated the trip as the “single most” unusual state of consciousness they had ever experienced. The remaining person rated it as among their top five. The study participants said they had experienced more psychological insight after taking the 25 mg of psilocybin than they had after the 1 mg placebo. The subjects also reported increased wellbeing two and four weeks after the study. This was measured from responses to statements such as, “I’ve been feeling optimistic about the future,” and “I’ve been dealing with problems well.”
As the scientists noted in their paper, “A predictive relationship was also found between brain entropy and longer-term mental-health changes—namely, improved wellbeing. Improved wellbeing could be predicted directly from acute increases in brain entropy as early as 1-h post dosing.”
A month after the study the study individuals also scored better on a test of cognitive flexibility. “Psilocybin seems to loosen up stereotyped patterns of brain activity and give people the ability to revise entrenched patterns of thought,” said first author Taylor Lyons, PhD, a research associate at Imperial College London. “The fact that these changes track with insight and improved well‑being is especially exciting.”
The scientists found that the subjects who had experienced the largest increases in brain entropy in the minutes to hours after taking psilocybin were the most likely to have increased insight the next day and increased wellbeing a month later. The researchers concluded that improved wellbeing was driven by the experience of insight.
The authors suggest that the study findings could improve treatment for people with mental illness using psilocybin, for example, by ensuring that the right dosage is used to produce the right amount of brain entropy to promote insight. “We already knew psilocybin could be helpful for treating mental illness,” Carhart-Harris said. “But now we have a much better understanding of how.”
In their paper the team concluded, “The present multi-modal neuroimaging study in healthy participants sheds light on the brain effects of first-time high-dose psychedelic use and the therapeutic action of psilocybin-therapy, suggesting that therapeutically relevant changes—i.e., improved wellbeing—can be forecast via an acute human brain action, i.e., an entropic brain effect, that is well-known to relate to the psychedelic experience … Results support a role for psychological insight in mediating the causal association between the entropic brain effect and potentially enduring improvements in wellbeing.”
The post Psilocybin-Induced Brain Changes May Explain Therapeutic Effects appeared first on GEN – Genetic Engineering and Biotechnology News.
Statement on Mental Health and Access to Evidence-Based Care
The IOCDF is proud to be a member of the Mental Health Liaison Group, which distributed the below statement. To learn more about appropriate treatment for OCD, including the use of medication and SSRIs, visit IOCDF’s Treatment Guide.
Following the MAHA Institute May 4, 2026, Summit entitled, “Mental Health and Overmedicalization,” and HHS’ MAHA Action Plan to Curb Psychiatric Overprescribing, the Mental Health Liaison Group (MHLG)— a nonprofit coalition of national organizations representing people with mental health and substance use conditions, family members and caregivers, providers of mental health and substance use treatment and support, advocates, and other stakeholders— reaffirms that improving mental health outcomes requires expanding access to comprehensive, evidence-based care.
MHLG recognizes that mental health care should be appropriate, individualized, and guided by clinical expertise and informed patient decision-making. The goal is the right care, delivered at the right time and tailored to each person’s unique needs.
A strong body of evidence supports a range of effective, individualized treatments, including psychotherapy and, when clinically appropriate, medications such as Selective Serotonin Reuptake Inhibitors (SSRIs). These treatments are effective for many individuals when appropriately prescribed, monitored, and supported as part of a comprehensive care plan. Individuals should be supported in working with their health care providers to determine and refine over time the care plan, including the benefits and risks, that best meets their needs, and engage in medical professional recommendation-based treatment, which for many may include psychotherapy and medication as part of a comprehensive approach to care.
Public discussion of mental health treatment should be informed by scientific evidence to support informed decision-making and patient-centered care. Misinformation or claims not supported by evidence may discourage individuals from seeking or continuing treatment, particularly at a time when many already face significant barriers to care.
MHLG supports policies that support ongoing research to expand access to comprehensive, evidence-based mental health services, reduce stigma, and strengthen the ability of individuals to initiate and remain engaged in appropriate care across the continuum of prevention, treatment, crisis and recovery. These priorities are consistent with MHLG’s principles, available at https://www.mhlg.org/about-us/
MHLG stands ready to engage with the Administration and policymakers as they consider and advance approaches impacting mental health care.
The Mental Health Liaison Group (MHLG) is a nonprofit coalition of national organizations representing people with mental health and substance use conditions, family members and caregivers, providers of mental health and substance use treatment and support, advocates, and other stakeholders committed to strengthening Americans’ access to mental health and substance use care. As trusted leaders in the field, our 100+ member organizations are dedicated to elevating the national conversation around mental health and substance use. Together, we work to advance federal policies that support prevention, early intervention, treatment, crisis response, and recovery services and supports.
The post Statement on Mental Health and Access to Evidence-Based Care appeared first on International OCD Foundation.
Genotype-Guided Antidepressants Could Have Long-Term Benefits
Prescribing antidepressants according to a patient’s genetic makeup could help manage depressive symptoms in the long-term, a clinical trial suggests.
The findings, in JAMA Network Open, suggest pharmacogenetic guidance could have extended benefits, which may not be apparent early on.
Primary results did not indicate that genotype-guided SSRI treatment was better than usual care at three months in A Depression and Opioid Pragmatic Trial in Pharmacogenetics (ADOPT PGx).
However, significantly more patients receiving genotype-guided therapy achieved the secondary endpoint of depression remission at six months.
“Although outcomes were similar early in treatment, differences emerged over time,” noted Kathryn Blake, PharmD, from Nemours Center for Pharmacogenomics and Translational Research in Jacksonville, Florida, and colleagues.
“These findings suggest a possible longer-term clinical benefit and indicate that future studies should focus on evaluating the durability and long-term impact of genotype-guided prescribing in the management of depressive symptoms.”
SSRIs are the most common pharmacotherapy for depression and variants in cytochrome P450 enzymes CYP2D6 and CYP2C19 can affect their metabolism, influencing exposure to this medication.
Indeed, guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) provide recommendations for SSRI prescribing when genotype information is available.
However, most psychiatry experts and practice guidelines for treating depression have not yet endorsed pharmacogenetic-informed therapy, citing insufficient evidence.
ADOPT PGx was a set of three randomized clinical trials, designed to test whether routine use of pharmacogenetic testing improves medication response among patients with depression, acute pain, or chronic pain.
The ADOPT PGx Depression trial included 221 children and 1239 adults, aged eight years or older who had experienced depression for three months or longer.
A total of 692 patients (47.4%) had an actionable phenotype, of whom 351 (50.7%) were assigned to the intervention, and 341 (49.3%) to usual care.
Among this group, two-thirds reported having depressive symptoms for more than two years, and three quarters were female. The vast majority were on pharmacologic treatment, at 87.1%, with just over half receiving nonpharmacologic treatment.
Participants were randomly assigned to genotype-guided SSRI prescribing or usual care to examine whether pharmacogenetic guidance improves depression over six months.
At three months, there were no significant differences between the intervention and usual care groups in the primary endpoint of change in Patient-Reported Outcomes Measurement Information System (PROMIS) depression T scores among patients with an actionable phenotype.
At this timepoint, there were also no differences in the secondary outcome of adverse effect severity.
However, another secondary endpoint of depression remission according to a PROMIS depression T-score of 16 or less was more likely with the intervention than usual care, at 48.3% (153 of 317 patients) versus 39.4%. (122 of 310 patients).
Based on this, the authors proposed: “These findings suggest that pharmacogenetic testing, including evaluation for CYP2D6 enzyme inhibition (phenoconversion), may offer meaningful benefit with longer follow-up.”
The post Genotype-Guided Antidepressants Could Have Long-Term Benefits appeared first on Inside Precision Medicine.
STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of cinnamon buns for the occasion. Spring has sprung, after all. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So here are some items of interest. Have a great day, everyone. …
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced several initiatives intended to rein in the prescription of selective serotonin reuptake inhibitors, the most widely prescribed class of antidepressants, which he has described as exceptionally difficult to quit, The New York Times writes. The initiative focuses on the most widely prescribed class of psychiatric medications, first-line treatments for depression and anxiety that include Zoloft, Lexapro, Paxil, and Prozac. In 2026. 16.7% of U.S. adults, or roughly one in six, reported currently taking one of these pills. The changes — new trainings, reimbursement mechanisms, and clinical guidelines — nudge clinicians to help patients get off medications, and to consider non-pharmaceutical interventions, like therapy, nutrition, and exercise.
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for patients with inflammatory bowel disease. But the company plans to advance the drug into late-stage testing, focusing on a growing subgroup of patients, STAT tells us. On Tuesday, trial investigators presented the results of a study that tested how well combining the drugs Tremfya and Simponi would stop the immune system from mistakenly attacking healthy tissues in the digestive tract. J&J tested the combined therapy in two Phase 2b clinical trials hitting both major forms of inflammatory bowel disease — ulcerative colitis and Crohn’s disease. In each trial, the combination performed better than the individual drugs, but did not meet the primary endpoint of clinical remission.

